Financials data is unavailable for this security.
View more
Year on year Lexicon Pharmaceuticals Inc had net income fall 73.74% from a loss of 101.94m to a larger loss of 177.12m despite a 766.19% increase in revenues from 139.00k to 1.20m.
| Gross margin | 92.47% |
|---|---|
| Net profit margin | -5,550.87% |
| Operating margin | -5,412.11% |
| Return on assets | -58.57% |
|---|---|
| Return on equity | -94.81% |
| Return on investment | -63.55% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Lexicon Pharmaceuticals Inc fell by 23.88m. Cash Flow from Financing totalled 187.96m or 15,611.30% of revenues. In addition the company used 161.90m for operations while cash used for investing totalled 49.94m.
| Cash flow per share | -0.7704 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.6639 |
|---|---|
| Tangible book value per share | 0.5406 |
More ▼
Balance sheet in USDView more
| Current ratio | 11.51 |
|---|---|
| Quick ratio | 11.49 |
| Total debt/total equity | 0.4146 |
|---|---|
| Total debt/total capital | 0.2931 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -30.22%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -13.91 |
